Gilat Satellite Networks (NASDAQ:GILT) reported a powerful start to 2026, delivering a "beat-and-raise" style performance in its first-quarter results. The company posted revenue of $110.5 million, a ...

The Australian Taxation Office has launched a stinging challenge against JB Hi-Fi (ASX:JBH), alleging the electronics giant overvalued The Good Guys’ logo copyright by more than ten times its actual ...

SFL Corp. (NYSE:SFL) hiked its quarterly cash dividend to $0.22 per share, extending one of the longest payout streaks in the maritime industry as strong offshore demand and new financing activity ...

Santos (ASX:STO) announced a final investment decision to proceed with the Agogo production facility tie-in project in Papua New Guinea. The brownfield development, sanctioned following approval from ...

EMVision Medical Devices (ASX:EMV) announced an expansion of its pivotal FDA De Novo trial, now incorporating acute ischaemia detection alongside its primary focus on haemorrhage identification. The ...

JB Hi-Fi (ASX:JBH) CEO Nick Wells has issued a cautionary outlook for the final quarter of the financial year, citing a tightening supply chain and rising costs for consumer electronics. Addressing ...

Eve Holding (NYSE:EMBJ), the electric vertical takeoff and landing (eVTOL) subsidiary of Embraer, reported financial results for the first quarter ended March 31, 2026, characterized by a deliberate ...

Buy-now, pay-later pioneer Zip (ASX:ZIP) has reaffirmed its FY26 earnings guidance, buoyed by a surge in transaction volumes and a commanding performance in the United States. Following a robust March ...

Australian household spending went up by 1.6% in March, marking an acceleration from the modest gains seen at the start of the year. Data released by the Australian Bureau of Statistics reveals that ...

Gentrack Group (ASX:GTK) has issued a market update revealing a strategic pivot towards global leadership and long-term expansion, even as it moderates its short-term financial outlook. The utility ...

AbbVie (NYSE:ABBV) shares are in focus after the biopharmaceutical giant released positive topline results for its investigational obesity treatment, ABBV-295. The Phase 1 multiple ascending dose ...

Immutep (ASX:IMM), a pioneer in LAG-3 immunotherapy, has reached a milestone in the treatment of autoimmune diseases. The company announced the completion of the single ascending dose portion of its ...